YOLFTbeta
Galapagos N.V.

Galapagos N.V.

0JXZ · LSE

30.40EUR-0.75 (-2.41%)

Price History

Full chart

Market Stats

Previous Close31.15
Open30.40
Day Range26.40 – 30.40
52-Week Range22.38 – 32.00
Volume0
Market Cap3.87B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.12
50-Day Avg35.57
200-Day Avg37.39

About

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Company Details

  • CEOMr. Henry O. Gosebruch
  • Employees196
  • HeadquartersSchaliEnhoevedreef 20 T, Mechelen, Belgium, 2800, UK
  • Websitehttps://lakefrontbio.com

Leadership

  • Mr. Henry O. GosebruchCEO & Executive Director · b. 1973
  • Mr. Aaron L. CoxChief Financial Officer · b. 1984
  • Ms. Christina Carlson J.D.Chief Operating Officer
  • Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D.Head of Investor Relations
  • Mr. Fred W. Blakeslee IIExecutive VP & General Counsel
  • Marieke VermeerschHead of Corporate Communication
  • Ms. Tania PhilippChief People Officer · b. 1972
  • Ms. Ellen Van Der AarHead of Development
  • Dr. Jeevan ShettyHead of Clinical Development Oncology
  • Ruiz AstigarragaHead of Manufacturing Cell Therapy

Financials

Income Statement

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Revenue151.61M155.92M317.85M885.80M530.26M--
Growth (%)-+2.84%+103.85%+178.69%-40.14%--
Operating Income-11.49M-89.80M-44.81M368.75M-178.63M--
Operating Margin-7.58%-57.60%-14.10%41.63%-33.69%--
Net Income54.01M-115.70M-29.26M149.85M-305.44M--
Net Income Margin35.62%-74.21%-9.21%16.92%-57.60%--
Interest Expense000000-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%--

Balance Sheet

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-31
Total Assets1.08B1.29B1.44B6.07B5.72B--
Total Liabilities324.64M274.29M225.25M3.19B3.05B--
Total Equity758.70M1.01B1.21B2.88B2.67B--
Cash99.98M149.71M199.24M----
Total Debt9.00K--19.56M23.04M--

Cash Flow

Currency: EUR2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Operating Cash Flow239.40M-147.03M-142.47M3.21B-427.34M-503.83M-500.54M--
Investing Cash Flow-7.29M-549.00K-15.91M-3.76B757.29M541.24M-1.25B--
Financing Cash Flow396.00M353.36M287.88M1.34B22.04M-3.88M-1.49M--
Capital Expenditure4.79M7.44M10.39M22.39M42.52M54.20M27.39M00

Earnings

Report DateDec 31, 2005Nov 13, 2015Mar 4, 2016Apr 29, 2016Jul 29, 2016Oct 27, 2016Feb 24, 2017Apr 28, 2017Jul 27, 2017Oct 27, 2017Feb 23, 2018Apr 26, 2018Aug 3, 2018Oct 25, 2018Feb 22, 2019Apr 26, 2019Jul 26, 2019Oct 24, 2019Feb 21, 2020May 8, 2020Aug 7, 2020Nov 6, 2020Feb 19, 2021May 7, 2021Aug 6, 2021Nov 5, 2021Feb 25, 2022May 6, 2022Aug 5, 2022Nov 4, 2022Feb 24, 2023May 5, 2023Aug 4, 2023Nov 3, 2023May 2, 2024Aug 1, 2024Oct 31, 2024Feb 13, 2025Apr 30, 2025Jul 23, 2025Nov 5, 2025Feb 24, 2026May 6, 2026Aug 10, 2026Nov 12, 2026
EPS Estimate----------------------------------------0.41-0.01--0.51-0.43-0.43
EPS Actual-0.07-0.70-1.460.79-0.08-0.520.97-0.28-0.74-0.72-0.59-0.73-0.420.270.27-0.89-0.866.03-1.79-0.78-1.77-1.25-0.890.14-0.98-0.990.25-0.20-0.290.33-3.150.350.080.391.370.14-0.770.38-2.33-1.60-3.0711.870.210.03-
Surprise----------------------------------------291.39%-30571.00%-141.18%107.00%-
Timing----------------------------------After-hoursAfter-hoursPre-market-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap3.87B
Enterprise Value-499.89M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
Book Value49.71
Revenue (TTM)990.57M
Gross Profit (TTM)669.75M
EBITDA568.92M
Profit Margin60.23%
Operating Margin-359.30%
Return on Equity20.12%
Return on Assets9.93%
Shares Outstanding0
Shares Float23.72M
Beta0.12
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%